

October 25th, 2022

Agenda

- Whitney Hartlage
- Zahra Kassamali Escobar
- Chloe Bryson-Cahn



Antibiograms: drug, bug, is that really it?

Optimizing UTI in the ED using a risk-factor stratified antibiogram

Presenting location	Percent susceptible of all Gram-negative pathogens in urinary cultures								
	CRO	FEP	ETP	MEM	GEN	ТОВ	NFT	TMP/ SMX	CIP
Community	97	NR	99	99	91	92	90	75	89
"Health- care Assoc"	79	82	96	99	84	87	70	64	74
LTCF	46	54	83	94	71	60	60	63	54

CRO: ceftriaxone; FEP: Cefepime; ETP: Ertapenem; MEM: Meropenem; GEN: Gentamicin; TOB: Tobramycin;

NFT: Nitrofurantoin; TMP-SMX: Trimethoprim-Sulfamethoxazole; CIP: Ciprofloxacin

Better represent a given patient




Antibiograms: drug, bug, is that really it?


- Advance techniques offer significant advantages over conventional antibiograms
- Being creative with variations could be performed to better optimize care
 - Optimizing ICU pneumonia with a <u>combination</u> <u>antibiogram</u>
 - Decreasing time to interventions using a rapid diagnostic testing result based antibiogram
 - Helping a failing patient with escalation antibiogram



Building the ID workforce from the ground up



Where are we now?



Strategies to increase interest in ID field – start early!



Exposure and visibility



Quality of experience



Mentorship



Understanding of specialty



Advocacy



ZKE's IDWeek Highlights



- Seeing friends and future friends in real life
- New Science to stretch the brain muscle
- Poster Sessions = research you can touch



When is the best time to get infected?




If Clocks could talk: Circadian regulation of lung injury and inflammation



SHAON SENGUPTA


Assistant Professor

University of Pennsylvania Perelman School of Medicine
Children's Hospital of Philadelphia
October 20th, 2022





Circadian: Circa (approximately) + Diem (Day



- 25-40% of transcriptome under circadian regulation
- Circadian transcriptomes are tissue specific
- Often involves vital pathways



Methods (II) **UK** biobank analyses




Large large-scale biomedical database and research resource

500,000 adult participants overall

For our study:

~100,000 adult participants

1-2 weeks data from hand worn devices (pre-validated for the evaluation of circadian rhythms)



Doherty et al, PLOS one, 2017

Outcomes:


Disease conditions (mainly infections)

Relative Amplitude of Circadian rhythms:




Poor circadian rhythms predict worse outcomes and longer hospital stay

Risk of hospital admission



Robustness of circadian rhythms


Length of stay



Courtesy Tom Brooks for Naik et al, Manuscript under review



Broader Speculations





Poster Session (N = 2246)

Let's GO PO: Impact of monthly feedback on a longitudinal intravenous to oral antimicrobial conversion initiative

Advent Health

Jillian E. Hayes, PharmD, BCIDP¹, Amy L. Carr, PharmD, BCIDP²
¹Duke University Hospital, Durham, NC; ²AdventHealth Orlando, Orlando, FL

Background

- Timely conversion of antimicrobials from intravenous (IV) to oral (PO) route has been shown to decrease cost and length of stay (LOS) without compromising safety and efficacy of therapy¹⁻³
- Use of PO antimicrobials may prevent catheterrelated complications, such as infection, emboli, and patient discomfort¹⁻³
- An existing, P&T-approved IV to PO policy allowed pharmacists to convert orders for fourteen antimicrobials and eligible patients at point of order verification


Objective

 To assess the impact of monthly, team-based feedback on percentage of antimicrobials administered orally during a pharmacist-driven IV to PO antimicrobial stewardship initiative


Methods

- Single center, retrospective comparative study of adult patients at AdventHealth Orlando
 - Pre-intervention: November 2019-October 2020
 - Post-intervention: November 2020-March 2022
- Stewardship strategy included provision of clinical team-based RePOrt Cards with monthly IV to PO conversion rates and team-based competition
- Primary outcome: days of therapy (DOTs) administered orally
- Secondary outcomes: individual antimicrobial oral conversion rates, IV to PO percent change, monthly cost differences. total cost differences

			Results			
Agent		Pre-Intervention PO DOTs	Post-Intervention PO DOTs	p-value	Estimated Monthly Cost Difference (\$)	Estimated Total Cost Difference (\$)
Total		42137 (62)	65215 (67)	0.0012		
	Azithromycin	2601 (39)	5696 (59)	<0.001	-140.02	-2735.27
	Ciprofloxacin	2137 (64)	3660 (68)	0.1761	-34.38	-439.46
	Clindamycin	154 (9)	277 (12)	0.0385	-101.89	-2591.31
	Doxycycline	5864 (77)	8672 (78)	0.4744	-121.19	-2838.95
	Fluconazole	5823 (67)	9024 (69)	0.2128	-22.85	-407.59
	Isavuconazonium	1411 (64)	1927 (72)	0.0688	-618.94	-12671.16
	Levofloxacin	4544 (85)	6485 (89)	0.0493	-54.43	-706.58
	Linezolid	3739 (56)	5666 (54)	0.7730	-2.16	+7434.29
	Metronidazole	2889 (29)	5279 (39)	0.0280	-54.37	-2300.53
	Minocycyline	2477 (64)	3105 (64)	0.5193	+3308.67	+60019.43
	Posaconazole	3740 (89)	5878 (93)	0.1086	-825.58	-20241.90
	Rifampin	407 (72)	662 (86)	0.0831	-10.87	-54.13
	SMX/TMP	5432 (96)	7249 (98)	0.0370	-217.70	-3461.07
	Voriconazole	919 (81)	1635 (70)	0.0018	+252.73	+5842.42



Example RePOrt Card



Discussion & Conclusions

- Provision of monthly, team-based feedback positively impacted IV to PO conversion rates
- Opportunities remain for higher-cost agents such as linezolid, minocycline, and voriconazole

References & Disclosures

- Cyriac JM, et al. J Pharmacol Pharmacother 2014;5:83-
- Béïque L, et al. Can J Hosp Pharm 2015;68:318-26.
- McCarthy K, et al. Aust Prescr 2020;43(2):45-48.

Disclosures All authors have nothing to disclose. Contact information: Jillian Hayes – jillian.hayes@duke.edu



Let's GO PO: Impact of monthly feedback on a longitudinal intravenous to oral antimicrobial conversion initiative



Jillian E. Hayes, PharmD, BCIDP¹, Amy L. Carr, PharmD, BCIDP²
¹Duke University Hospital, Durham, NC; ²AdventHealth Orlando, Orlando, FL

Pre-intervention

Measure PO antibiotic days of therapy Nov '19 – Oct '20



Intervention

RePOrt Cards for pharmacists to convert orders from IV to PO at order verification



Post-intervention

Measure PO antibiotic days of therapy Nov '20 – Mar '22

IM Team RePOrt Card: April 2021


LET'S GO PO Challenge:

- Starting November 16, 2020, IV to PO conversion for antimicrobials included in SOP #200.326A will be tracked.
- The team with the highest % of orders administered orally AND our most improved team will win a prize!

Team and Department Metrics: April 2021


	Average Percentage of Select Antimicrobial Orders Administered Orally (%)	Goal (%)
Cardiology Team	52	
Critical Care/EM	48	1
Internal Medicine	62	1
Neurology	76	75
Oncology	72]
Surgery	66	1
Department	63	1

Drug-Specific Breakdown:



^{**}No DOTs of isavuconazole, Posaconazole, or voriconazole were reported for IM areas for April 2021.

Month-by-Month Results:



Let's GO PO: Impact of monthly feedback on a longitudinal intravenous to oral antimicrobial conversion initiative



Jillian E. Hayes, PharmD, BCIDP¹, Amy L. Carr, PharmD, BCIDP²
¹Duke University Hospital, Durham, NC; ²AdventHealth Orlando, Orlando, FL

_			
- 10)	es	ш.	
- 11	_		

Agent		Pre-Intervention PO DOTs	Post-Intervention PO DOTs	p-value	Estimated Monthly Cost Difference (\$)	Estimated Total Cost Difference (\$)
Total		42137 (62)	65215 (67)	0.0012		
	Azithromycin	2601 (39)	5696 (59)	<0.001	-140.02	-2735.27
	Ciprofloxacin	2137 (64)	3660 (68)	0.1761	-34.38	-439.46
	Clindamycin	154 (9)	277 (12)	0.0385	-101.89	-2591.31

So THIS is how we could use NHSN AUR data!



Nursing Stewardship Education

A Pre-Post Interventional Study on the Impact of Asynchronous Microlearning of Antimicrobial Stewardship Principles among Nursing Staff at a Large Academic Medical Center



Laura J. Bobbitt, PharmD; Christo L. Cimino, PharmD, BCPS, BCIDP; Kim V. Garvey, PhD, MLIS; Leanna S. Craft, MSN, RN, SCRN; Nicole A. Eichenseer, MSN, RN; George E. Nelson, MD Vanderbilt University Medical Center, Nashville, Tennessee



STUDY DESIGN



One case-based, multiple-choice question per day





Delivered via text message or email



Instant feedback with explanation

- Topics such as:
 - Defining antimicrobial resistance & understanding nursing AS roles
 - Differentiating urinary tract infections from asymptomatic bacteriuria
 - Identifying sepsis and importance of early antibiotic administration
 - Ensuring appropriate indications prior to obtaining cultures
 - · Identifying intravenous (IV) to oral (PO) conversions
 - · Identifying opportunities for antibiotic de-escalation
 - Taking accurate allergy histories
 - Recognizing common antibiotic adverse events (AE)
- KAP survey pre- and post-course
- · Survey results compared via Wilcoxon signed-rank test




A Pre-Post Interventional Study on the Impact of Asynchronous Microlearning of Antimicrobial Stewardship Principles among Nursing Staff at a Large Academic Medical Center



Laura J. Bobbitt, PharmD; Christo L. Cimino, PharmD, BCPS, BCIDP; Kim V. Garvey, PhD, MLIS; Leanna S. Craft, MSN, RN, SCRN; Nicole A. Eichenseer, MSN, RN; George E. Nelson, MD Vanderbilt University Medical Center, Nashville, Tennessee





No statistically significant change in "I am familiar with the term antibiotic resistance" and "I can usually tell if my patient's change in clinical status is due to a possible infection."



A Pre-Post Interventional Study on the Impact of Asynchronous Microlearning of Antimicrobial Stewardship Principles among Nursing Staff at a Large Academic Medical Center



Laura J. Bobbitt, PharmD; Christo L. Cimino, PharmD, BCPS, BCIDP; Kim V. Garvey, PhD, MLIS; Leanna S. Craft, MSN, RN, SCRN; Nicole A. Eichenseer, MSN, RN; George E. Nelson, MD Vanderbilt University Medical Center, Nashville, Tennessee



CONCLUSIONS

- Education on the role of nurses in AS provided in an asynchronous, brief educational format via a mobile platform resulted in statistically significant improvement in 90% (18/20) of topics
- After course completion, participants felt more confident in their ability to participate in key AS activities
- Nurses are integral members of a multidisciplinary AS team and should be empowered to help reduce unnecessary antibiotic use in their patients
- This study forms the basis for expanded AS educational efforts for all healthcare professionals



1488 – The Economic Burden of AEs on OPAT

- Multicenter retrospective claims analysis from UT, 2020
- 248,843 patients met criteria for an OPAT AE

Rapid Fire Presenter(s)



Mauricio Rodriguez, PharmD, MS-HEOR, BCPS, BCCCP, BCIDP

Senior Director, Health Economics Outcomes Research (HEOR)

Spero Therapeutics (Former Employee) San Antonio, TX, United States

Disclosure: Disclosure(s): Spero Therapeutics: Employee ()

Table 2. Mean inpatient hospital LOS associated with OPAT AEs

Adverse Event	ICD-10 Code	Mean LOS (days, 95% CI)
C. difficile	A04.72	4.30 (3.78-4.82)
Blockage	T83.091A	2.57 (1.17-3.97)
Phlebitis	T82.868A	4.51 (3.84–5.17)
IV Complications	T80	6.43 (5.87-6.98)
Thrombosis	182.409, 126.9	2.95 (2.81-3.10)
Central Line–Associated Bloodstream Infection	T80.211A	7.04 (6.39–7.70)



1488 – The Economic Burden of

AEs on OPAT






Mauricio Rodriguez, PharmD, MS-HEOR, BCPS, BCCCP, BCIDP

Senior Director, Health Economics Outcomes Research (HEOR)

Spero Therapeutics (Former Employee)
San Antonio. TX. United States

e(s): Spero Therapeutics:

Figure 1.



OPAT is outpatient parenteral antimicrobial therapy.

- Multicenter retrospective claims analysis from UT, 2020
- 248,843 patients met criteria for an OPAT AE



[†] Numbers in parentheses represent projected U.S. counts based on actual values in Utah.

QUESTIONS?





Next Dayth, 2022

Agenda

- Will
- Rupali
- John



Implt. Compendium I, WED, Schafzin

- Guidance is to help move info from science to practice
- Successful implementation matched to orgs context (resources)
- Every chapter has an implementation section
- Dedicated chapter on implementation
- Education is not sufficient
- Regulatory expectation is to implement EB interventions



Implt. Compendium 2, WED, Schafzin

- 4Es approach (engage, educate, execute, evaluate)
 - Think big and small, engage and envision, additional steps
- SSI prevention: since takes time, process measures play larger role
 - QI tools
 - HFE(automated reminders for example)
 - Multidisciplinary
- Eating an elephant, tackle one thing at a time, test and learn and change and repeat, 30K level



Implt. Compendium 3, WED, Schafzin

- Leadership engagement
- Frontline engagement
- Technical work vs adaptive work
 - Tech: the evidence, clear needs to be done
 - Adaptive: how work gets done in context, req learning, conscious and unconscious barriers, attitudes, beliefs, values, feedback, culture
- Process observation, gemba walk
- Purposeful design



TMP for SSTI, Fri, Dornberg

- Historically it was believed that GAS was intrinsically resistant to TMP-SMX
- No CLSI bp for TMP-SMX GAS
- Can use EUCAST data, ~1.5% resistance, higher in India (12-78%)
- In studies of clinical use, lots of confounders
- Thymidine issue (didn't understand this part, need to review)
- Clinda vs TMP/SMX NEJM RCT



SHEA Compendium, Wed

- CA-MRSA (USA300) has invaded the hospital
- Epi and Recent Trends MRSA MMWR, more MRSA infections
- 2014 unresolved issues that remain unresolved:
 - Decolonization outside the ICU
 - Mupirocin/chlorhexadine resistant
 - MRSA+ HCW
 - Universal MRSA decolonization



VAP Prevention I, Wed, Klompas

- Many strategies to prevent? List is long
- Build a framework? The VAP prevention paradox: VAP rates go down, but LOS, vent days, death don't change. Problem: VAP subjective
- Focus rec: impact objective outcomes like duration, VAE, mortality, etc
- See essential practices, includes oral care with tooth brushing, w/o chlorhexidine
- Selective oral/digestive decon: good studies w/ improved mortality, no assoc w/ drug resistance, may not generalize to high DR settings



VAP Prevention 2, Wed, Klompas

• Subglottic secretion drainage, rec not sustained







Polio update -RJ























